Takeda U.S. Unit Signs With Metabolex To Develop New Drugs
This article was originally published in PharmAsia News
Takeda Pharmaceuticals' U.S. subsidiary has signed a contract with Metabolex to share research into new drugs. Metabolex of the United States specializes in treatments for diabetes and other metabolic diseases. Under the arrangement with Takeda San Francisco, the firms are to collaborate on developing a drug based on the Metabolex technology. Metabolix already has four drugs undergoing clinical trials, the most advanced of them just completed Phase II tests. (Click here for more
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.